Because we showed an interplay between casp3 activation and Aβ42 oligomers production, we tested the NSAID flurbiprofen described as potential anti-Alzheimer’s disease drug [39] in combination with a pan caspase inhibitor, Z-VAD-fmk. Here, CASP3 is linked to early-onset autosomal dominant Alzheimer disease.